Background
==========

Sexually transmitted diseases (STDs) are fairly common in people of reproductive age; more than 50% of new STD infections occur in adolescents. However, only 50% to 80% of reportable STDs that occur in the United States are actually reported \[[@B1]\]. Testing for STDs can result in negative cytology, that is, laboratory test results that revealed reactive cellular change (RCC) or atypical squamous cells of undetermined significance (ASCUS). RCC or ASCUS is routinely screened for, but they are not associated with neoplasms or preneoplastic stages known as squamous intraepithelial lesions (SILs). RCCs are cytological alterations related to inflammation or irritation but, whether subtle or marked, are typically not associated with human papillomavirus (HPV) infection. Common features of RCCs include the formation of small perinuclear halos, mild nuclear enlargement or nuclear degeneration, hyperchromasia, cytoplasmic pseudokeratinization, cytoplasmic vacuolization, and notably a background of inflammation. The abnormal cytology of ASCUS can usually be distinguished from RCC, but does not meet all criteria of HPV-infected koilocytes \[[@B2]\].

With the exception of a few organisms that cause sexually transmitted infections (STIs) such as *trichomoniasis*or *candidiasis*, most inflammatory agents are only rarely recognized under the microscope and usually produce nonspecific cytopathic effects. For example, bacterial vaginosis (BV) is a leading cause of abnormal vaginal discharge as a sequel of gynecologic conditions, including endometritis, pelvic inflammatory disease (PID), post-surgical abortion, post-hysterectomy infection, and cervical intraepithelial neoplasia \[[@B3]\]. However, few attempts have been made to identify the etiologic organisms of BV, and diagnoses have relied only on the presence of common \"clue cells\" detected in cervical swabs \[[@B4],[@B5]\]. The prime manifestation of BV constitutes a massive micro-ecologic alteration of vaginal flora characterized by decreased *Lactobacillus spp*., logarithmically-increased *Gardnerella vaginalis*, and the presence of potentially pathogenic bacteria, including *Bacteroides, Peptococcus, Mobiliuncus*, *Ureaplasma urealyticum*, and *Mycoplasma spp*. *Mycoplasma spp*. and *U. urealyticum*are most frequently detected in the vaginal tract \[[@B6]\], and are strongly associated with infertility, intra-amniotic infection, postpartum infection, and pelvic inflammatory disease (PID) \[[@B1]-[@B5]\]. The multiple strains of *Mycoplasma*are the only cell wall-deficient, membrane-bound organisms capable of independent self-replication: they include *Mycoplasma hominis, M. genitalium, M. primatum, M. spermatophilum*, and *M. penetrans*\[[@B7],[@B8]\].

Despite the fact that many pathogens are not detected by Gram stain, Gram-stained vaginal secretions are still accepted as the diagnostic gold-standard, rather than the culture of secretions. With the advent of advanced techniques such as those based on liquid-based cytology \[[@B9]-[@B13]\], it is now feasible to accurately and efficiently identify microorganisms in cervicovaginal swab specimens of asymptomatic patients with multiplex PCR or DNA chip. Although detection of infectious organisms is not the primary goal of cervical cytology, it can be an important component of screening in asymptomatic patients or subtle disease. We aimed to estimate the incidence of STIs in healthy women of reproductive age with negative cytologic findings by multiplex PCR and find any correlation of HPV infection with specific pathogens.

High-throughput technology including hybrid capture 2 (HC2) and DNA microarray has been currently adopted to detect HPV \[[@B14]\]. HC2 is a relatively easy method with high screening power, but it is unable to genotype or excludes low-risk HPV types. DNA microarray can identify specific genotypes, and can also detect co-infection in a single sample, but is labor-intensive. Despite widely available high-throughput technology for the detection of microbes or HPV, few studies of STDs and HPV with high fidelity data exist due to lack of a gold standard. We therefore designed multiplex PCR assays to compare with the available methods of HC2 and HPV DNA microarray, and analyzed discordant results by direct sequencing.

Methods
=======

A total of 235 married and sexually active women (mean age of 37.9 y; ages range 21 to 48 years) were recruited by the Department of cytopathology of Yonsei University College of Medicine for this study. Specimens collected from cervical liquid-based cytology medium were negative for intraepithelial lesions. Participants had no clinical STD symptoms that required a clinical visit, no history of STDs, and no abnormal Papanicolau tests (Pap smear) results. We also excluded patients with SIL or carcinoma, postmenopausal women, or those with previous operative or therapeutic history related to gynecologic disease. The study protocol was approved by the local institutional review board, and written informed consent was obtained from all participants.

Multiplex-PCR for STI
---------------------

### Pretreatment and DNA Extraction of cervicovaginal swab specimens

Cervix swab samples were collected from the posterior fornix and lavaged with 5 mL of sterile phosphate-buffered saline (PBS pH 7.4). PreservCyt specimens were tested by Seeplex^®^STI Master ACE Detection (Seegene, Seoul, Korea) or Seeplex^®^HPV4A ACE Screening (Seegene) within 1 month of collection. PreservCyt transport medium containing endocervical cells was vortexed vigorously, and 1-mL samples were transferred into 1.5-mL polypropylene tubes, each containing 1 mL of PreservCyt transport medium. The tubes were centrifuged at 13,000 × *g*for 15 min at 20°C. Supernatants were discarded, and each cellular pellet was suspended in 200 μL of PBS. DNA was purified from these samples using the QIAamp DNA Mini Kit according to the manufacturers\' instructions (Qiagen, Hilden, Germany). The quality and quantity of purified DNA was measured by spectrophotometry.

### Multiplex PCR

Four primer sets were tested by STI multiplex PCR: Seeplex^®^STI Master Panel 1, 2, 3, and HPV4A ACE Screening. Panel 1 comprised of *Neisseria gonorrhoeae (NG)*, *Mycoplasma hominis (MH), Chlamydia trachomatis (CT)*, *Ureaplasma urealyticum (UU)*, and *M. genitalium (MG)*. Panel 2 comprised *Trichomonas vaginalis (TV), Gardenerella vaginalis (GV), Bacteroides fragilis (BF), Mobiluncus curtisii (MC)*, and *M. mulieris (MM)*. Panel 3 comprised *Candida glabrata (CG), C. tropicalis (CT1), C. parapsilosis (CP)*, *Group β- streptococcus*(*GBS*), and *C. albicans (CA)*. Primers were designed such amplicon sizes differed sufficiently to be distinguished from each other; they ranged from 212 bp (*UU*) to 635 bp (*CG*) and the internal control was 981 bp. Optimized multiplex PCR was performed in 20 μL reactions containing DNA template, primer mixture (final concentration of each primer, 3 pmole), 2× Master mix (Seegene, Korea) and 30 μg/mL of 8-methoxypsoralen (MOP), which prevents contaminating DNAs from being amplified. PCR amplification was performed in an Applied Biosystem 9700 thermal cycler (Perkin-Elmer, Boston, MA, USA) with the following conditions: 94°C for 15 min, followed by 40 cycles of 94°C for 30 sec, 63°C for 1.5 min (or 60 °C for 1.5 min for HPV4A ACE Screening), and 72°C for 1.5 min; and final extension at 72 °C for 10 min. A DNA plasmid was added to the PCR reaction mixtures as an internal control to be co-amplified with the target DNAs collected from the clinical specimens. Sterile deionized water was included as a negative control in each batch of PCR reactions. Target organisms, target genes, accession numbers, and expected amplicon sizes are summarized in Additional File [1](#S1){ref-type="supplementary-material"}.

### Multiplex-PCR-

HPV was detected with the Seeplex^®^HPV4A ACE screening kit for 14 HR-HPV types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 67, 68, and 70) and 5 LR-HPV-types (6, 11, 42, 43 and 44). In addition individual genotyping of HPV-16 and HPV-18 was performed with different multiplex primer mixtures.

### Hybrid capture 2 (HC2)

HC2 HPV test (Digene, Gaithersburg, MD) was performed according to the manufacturer\'s instructions to detect HPV, starting from 4 mL of liquid cytology specimens. The HC2-13 HR probe cocktail detects HPV types-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68. Relative light unit/cut-off ratio between 1 and 2.5 relative light units was used as the threshold for a positive result.

### HPV Microarray

We used an HPV genotyping DNA microarray (Biocore Ltd, Korea, Seoul) with multiple oligonucleotide probes of L1 sequence of 26 types of HPV (HR: 16,18, 26, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 69, 73 and 53; LR: 70, 6, 11, 32, 34, 40, 42, 43, 44, 54, 55, 57, 61 and 62). L1 consensus PCR products were hybridized to the probes on the microarray, and HPV genotypes were identified with a fluorescence scanner (GenPix 4000B, Axon Instruments Inc, CA) with a 532 nm laser for excitation of Cy3.

### DNA sequencing and cloning

Discrepant results among the HC2, DNA microarray, and Seeplex^®^HPV4A ACE screening kit results were resolved by sequencing with the PGMY09/PGMY11 primer sets. PCR reactions (20 μL) were performed with 2 μL template DNA, 1 μM of each primer, and 2x Master mix (Seegene, Korea). PCR amplification was carried out with an Applied Biosystem 9700 thermal cycler (Perkin-Elmer) with the following parameters: 94°C for 15 min followed by 40 cycles of 94°C for 30 sec, 55°C for 1 min, and 72°C for 1 min, and a final extension at 72°C for 10 min. The entire volume of each PCR reaction was run on a 2% agarose/1× Tris-acetate-EDTA gel containing ethidium bromide. The 465-bp bands amplified by the PGMY09/PGMY11 primers were excised and transferred to 1.5-mL tubes. DNA was extracted with the QiaexII gel extraction system (Qiagen, Valencia, CA) and eluted with 20 μL Tris-EDTA buffer. The products were ligated into the pGEM-T Easy vector (Promega, Madison, WI), transformed into chemically-competent JM109 cells, and plated onto two Luria-Bertani (LB) plates containing ampicillin, isopropyl-D-thiogalactopyranoside, and 5-bromo-4-chloro-3-indolyl-D-galactopyranoside. DNA was extracted from the white colonies with the Qiaprep Spin kit (Qiagen) and sequenced with the ABI Big Dye Terminator v3.1 cycle sequencing kit and an ABI 377 sequencer (Applied Biosystems, Foster City, CA). Sequences were trimmed to exclude the amplification primer and vector sequences, and the resulting fragments were analyzed by BLAST <http://www.ncbi.nlm.nih.gov/blast>. The top hit for each sequence was listed as the genotype.

Statistical Analysis
--------------------

The agreement rate of kappa value with respect to a quantitative measure of agreement between assay methods was calculated. The sensitivity of the HPV multiplex PCR, HC2 or DNA microarray relative to DNA direct sequencing is the proportion of positive samples in each assay among sequencing positive samples, and the specificity is the proportion of negative samples in each assay among those negative samples in direct sequencing. The positive predictive value is the proportion of positive samples in DNA direct sequencing, among those positive samples in each assay, and the negative predictive value is the proportion of negative samples in sequencing among those negative in each assay.

Results
=======

Prevalence of STIs
------------------

The overall prevalence of STIs in cervicovaginal samples of negative cytology, which was not clinically presented with BV, was 97.9% (230/235). Most patients of 84.9% (202/230) were co-infected by more than two microbes, whereas twenty-eight specimens were infected by a single agent (Fig. [1](#F1){ref-type="fig"}). Table [1](#T1){ref-type="table"} is an example to interpret data shown in Fig. [1](#F1){ref-type="fig"} Most common agents we detected were *GV*found in 88.1% of the samples (207/235), *UU*in 63.0% (148/235), and *GBS*in 26.4% (62/235). The most frequently co-infected organism was observed in *MH*infections, which was commonly observed with *UU*(p = 0.000), *MM*(p = 0.000), *MC*(p = 0.000), and *CT*(p = 0.009). In addition, *GV*and *MC*(p = 0.014), *MC*and *MM*(p = 0.003), *MG*and *CA*(p = 0.006), and *TV*and *GBS*(p = 0.011) were similarly detected in the same samples.

![**Sexually transmitted infection and human papillomavirus (HPV) multiplex PCR**. Representative data of multiplex PCR with four multiplex primer mixes: Seeplex^®^STI Master Panel 1 (MP1), 2 (MP2), 3 (MP3) and HPV4A ACE Screening. Panel 1 (B31) primers were designed so that amplicons were different sizes: 214 bp (*NG*), 253 bp (*MG*), 348 bp (*CT1*), 435 bp (*UU*), 502 bp (*MH*), and 800 bp (internal control). Panel 2 (B32) amplicons were 155 bp (*MM*), 197 bp (*MC*), 343 bp (*BF*), 509 bp (*GV*), and 647 bp (*TV*).](1471-2334-10-284-1){#F1}

###### 

Interpretation of data shown in Figure 1.

  ---------------------------------------------------------------------------------------------------------------------------------------
  Sample \#   MP1                                                 MP2                              MP3                 HPV4AACE
  ----------- --------------------------------------------------- -------------------------------- ------------------- ------------------
  1           *M. hominis, U urealyticum/parvum*                  *G. vaginalis, B fragilis*,\     *C. tropicalis*     HRC
                                                                  *M. curtisii*                                        

                                                                                                                       

  2           *M. hominis, C. trachomatis*                        *G. vaginalis, M. curtisii*      *-*                 HPV-16

                                                                                                                       

  3           *M. hominis, U urealyticum/parvum, M. genitlaium*   *G. vaginalis, M. curtisii*,\    *GBS*               HPV-16
                                                                  *M. mulieris*                                        

                                                                                                                       

  4           *M. hominis, C. trachomatis*,\                      *T. vaginalis, G. valginalis*    *C. glabrata*       HPV-16, HPV 6/11
              *U urealyticum/parvum*                                                                                   

                                                                                                                       

  5           *U urealyticum/parvum*                              *-*                              *C. parapsilosis*   HRC

                                                                                                                       

  6           *M. hominis, C. trachomatis*,\                      *G. vaginalis*                   *-*                 HRC
              *U urealyticum/parvum*                                                                                   

                                                                                                                       

  7           *-*                                                 *G. vaginalis, M. curtisii*,\    *C. glabrata*       HRC, HPV-6/11
                                                                  *M. mulieris*                                        

                                                                                                                       

  8           *C. trachomatis, U urealyticum/parvum*              *G. vaginalis, M. mulieris*      *C. albicans*       HPV-16, HRC

                                                                                                                       

  9           *C. trachomatis, U urealyticum/parvum*              *-*                              *GBS*               HRC, HPV-18

                                                                                                                       

  10          *M. hominis, U urealyticum/parvum, M. genitalium*   *-*                              *GBS*               HPV-16

                                                                                                                       

  11          *-*                                                 *T. vaginalis, G. vaginalis*,\   *C. albicans*       HRC, HPV-18
                                                                  *B. fragilis*                                        

                                                                                                                       

  12          *N. gonorrhoeae*                                    *T. vaginalis, G. vaginalis*     *C. glabrata*       HPV-18
  ---------------------------------------------------------------------------------------------------------------------------------------

HRC: HPV high-risk common 11 types

HPV infection status
--------------------

The incidence of HPV in negative cytology varied according to the assay used: multiplex-PCR, 24.7% (58/235); HC2, 21.3% (50/235); HPV chip, 22.6% (53/235). The HPV types which were most often detected included HPV-16 (PCR, 20.7%; DNA Chip, 26.4%) and HPV-18 (PCR, 8.6%; DNA chip, 11.3%). Less commonly detected HPV types included 51, 58, and 33 in the HR group, and 70 and 6 in the LR group. Eighteen LR-HPV types were detected by PCR (31.0%), eight by DNA microarray (15.1%), and 11 by direct sequencing. Infection with multiple genotypes was detected in 13 specimens (22.3%) by PCR and 14 specimens (26.4%) by DNA microarray.

Comparison between HPV Multiplex PCR, HC2, and Microarray
---------------------------------------------------------

Overall, there are good agreements between methods to detect HPV, and multiplex PCR showed the highest agreement ratio with relation to direct sequencing (PCR vs. sequence, Kappa = 0.8558; HC2 vs. sequence, Kappa = 0.8156; Chip vs. sequence, Kappa = 0.8539; PCR vs. HC2, Kappa = 0.7179; PCR vs. Chip, Kappa = 0.8082; HC2 with chip, Kappa = 0.7915;).

Because HC2 detects only HR group, 11 specimens with LR-HPV infection were excluded in the analytic sensitivity/specificity. The results of 25 of 235 specimens (10.6%) were discordant among methods; therefore these specimens were analyzed by direct sequencing. DNA chip produced more false negative results than HPV multiplex PCR and HC2 did (Table [2](#T2){ref-type="table"}).

###### 

Comparison of PCR, HC2, and Chip methods in 25 discordant samples.

       PCR     HC2             Chip    Sequence   False +           False -
  ---- ------- --------------- ------- ---------- ----------------- ---------------
  1    LR      N               N       N          PCR               
                                                                    
  3    LR      N\*\*           N       70         PCR **^1^\***     Chip
                                                                    
  4    N       HR              N       53         HC2 **^2^\***     PCR/Chip
                                                                    
  5    HR      HR              N       66         HC2 **^3^\***     Chip
                                                                    
  6    HR      HR              N       54         PCR/HC2           Chip
                                                                    
  7    LR      HR              N       11         HC2               Chip
                                                                    
  8    N       HR              OTHER   83         HC2 **^4^\***     PCR **^4^\***
                                                                    
  9    N       HR              OTHER   52         Chip: mistyping   PCR
                                                                    
  10   N       HR              OTHER   N          HC2/Chip          
                                                                    
  11   N       HR              N       39                           PCR/Chip
                                                                    
  12   HR      N\*\*           70      70         PCR               
                                                                    
  13   N       HR              16      16                           PCR
                                                                    
  14   HR      N               51      51                           HC2
                                                                    
  15   HR      N\*\*           11      11         PCR               
                                                                    
  16   HR      N\*\*           70      70         PCR               
                                                                    
  17   N       HR              16+39   16+39                        HC2
                                                                    
  18   N       HR              54      54         HC2 **^5^\***     PCR **^5^\***
                                                                    
  19   N       HR              N       N                            HC2
                                                                    
  20   HR      HR              70      70         PCR               HC2
                                                                    
  21   N       HR              N       N          HC2               
                                                                    
  22   N       HR              other   N          HC2/Chip          
                                                                    
  23   18+HR   N               18+70   18+70                        HC2
                                                                    
  24   HR+LR   N (equivocal)   73+43   73+43                        HC2
                                                                    
  25   HR      N               51      51                           HC2

PCR (20 types; 18 HR types+2 LR types): 16, 18, 26, 31, 33, 35, **39**, 45, 51, **52**, **53**, 56, **58**, 59, **66**, 68, 73, and 82 + 6 and **11**

HC2: (13 HR types) 16,18,31,33,35,**39**,45,51,**52**,56,58,59, and 68

Chip (26 types; 18 HR types+8 LR types): 16,18, 26, 31, 33, 35, **39**, 45, 51, **52**, 56, **58**, 59, **66**, 68, 69, 73, 53 and LR: **70**, 6, **11**, 32, 34, 40, 42, 43, 44, **54**, 55, 57, 61, 62

1\*: PCR LR does not cover HPV-70 type.

2\*: HC2 HR does not cover HPV-53 type.

3\*: HC2 HR does not cover HPV-66 type.

4\*: HC2 and PCR PR do not cover HPV-83 type.

5\*: PCR LR does not cover HPV-54 type.

6\*: PCR LR does not cover HPV-67 type.

\*\*: HR2 was not considered in this analysis because HR2 excludes LR HPV types.

Performance characteristics of the diagnostic test are shown in Table [3](#T3){ref-type="table"} . Positive predictive values associated with multiplex PCR and microarray were greater than 90%; the negative predictive value and accuracy rates were greater than 95%. HPV multiplex PCR and DNA microarray methods showed analytical sensitivities greater than 85%, and analytical specificity was nearly 100% with all methods. The area under the curve (AUC) was the highest for multiplex PCR at 0.922. Receiver operating characteristics (ROC) are shown in Fig. [2](#F2){ref-type="fig"}. However, there were no statistically significant differences between the three methods tested.

###### 

Efficacy of multiplex-HPV PCR, HC2, and Chip, based on direct sequencing.

             True Positive     True Negative       False Positive      False Negative    HPV-all- Negative                       
  ---------- ----------------- ------------------- ------------------- ----------------- ------------------- ------------------- --------------
  **PCR**    48                175                 5                   7                 235                                     
                                                                                                                                 
  **HC2**    45                173                 6                   9                 233                                     
                                                                                                                                 
  **Chip**   47                176                 4                   8                 235                                     
                                                                                                                                 
             **Sensitivity**   **Sensitivity-l**   **Sensitivity-u**   **Specificity**   **Specificity-l**   **Specificity-u**   **AUC**
                                                                                                                                 
  **PCR**    87.2727           78.4646             96.0808             97.2222           94.8214             99.6230             0.922
                                                                                                                                 
  **HC2**    83.3333           73.3932             93.2735             96.6480           94.0113             99.2848             0.900
                                                                                                                                 
  **Chip**   85.4545           76.1369             94.7722             97.7778           95.6243             99.9312             0.916
                                                                                                                                 
             **PPV**           **PPV-l**           **PPV-u**           **NPV**           **NPV-l**           **NPV-u**           **Accuracy**
                                                                                                                                 
  **PCR**    90.5660           82.6965             98.4356             96.1538           93.3599             98.9478             94.8936
                                                                                                                                 
  **HC2**    88.2353           79.3926             97.0779             95.0549           91.9051             98.2048             93.5622
                                                                                                                                 
  **Chip**   92.1569           84.7782             99.5356             95.6522           92.7055             98.5988             94.8936

-l: lower limit of 95% confidence interval, -u: upper limit of 95% confidence interval.

AUC: area under the curve

PPV: positive predictive value,

NPV: negative predictive value

![**ROC curve to detect HPV using multiplex-PCR, HC2, and DNA microarray**. ROC curve areas and 95% confidence intervals between each of the three different methods are shown.](1471-2334-10-284-2){#F2}

Analysis of the correlation between STIs and HPV infection
----------------------------------------------------------

Specimens positive for LR-HPV infection were frequently co-infected with *C. trachomatis*(4/18 HPV LR+ \[22.2%\]; p = 0.049), whereas those with HR-HPV were frequently detected with *GBS*(6/37 HPV HR+ \[16.2%\]; p = 0.016).

Discussion
==========

Reports of the incidence of STIs in asymptomatic women are not currently available, because of few attempts to recognize STI species despite advanced techniques based on liquid-based cytology \[[@B9]-[@B13]\].

We found that the overwhelming majority of patients with negative cytologic findings were positive for at least one STI (97.9%); many were positive for multiple infectious agents (84.9%). These results are surprising in that we did not observe high rates of infection with microbes that are typically widespread, such as *N. gonorrhea*and *C.trachomatis*\[[@B10],[@B13]\]. In more than 25% of the samples, we detected microbes that cause asymptomatic, dormant non-gonococcal and non-chlamydial infections, such as *G. vaginalis, U. urealyticum, Group β streptococcus*, and *M. hominis*. Microbes detected in less than 2% of the specimens were *CT-1, NG*, and *C. parapsilosis (CP)*\[[@B13]\].

*MH*was often detected in the same sample with other microbes, such as *UU, M. mulieris (MM), M. curtisii (MC)*, and *CT*. However, co-infection of multiple mycoplasma strains has rarely been reported \[[@B15]\].

Because HPV and STIs rely on the same route of infection, this increased risk of HPV infection in patients with STIs was expected. Studies of women visiting STD clinics have reported a greater prevalence of HPV infection in this group than in the general population \[[@B16],[@B17]\]. In one study, approximately half of the women evaluated at an STD clinic were infected with genital HPV, including HPV types-16, 83, 56, 52, and 59 (HR group) and 66 (LR group) \[[@B16]\]. In the present study of 235 asymptomatic women who had negative cytology results, we found that approximately 20% were infected with HPV. Using a genotyping microarray or grouping multiplex PCR, the most common HR types we detected were HPV types-16, 18, 51, 58, and 33, and the most common LR type was HPV-70. Epidemiologic data concerning HPV-types differ based on the method of detection used and the target samples. Multiple infections with more than two different HPV genotypes were found in 22% to 26% of the specimens, and HPV-16 was most detected (50%).

Specimens infected with LR-HPV were frequently co-infected with *CT*, whereas those with HR-HPV were coinfected with *GBS*. The fact that *CT*associates with LR-HPV rather than HR-HPV suggests that CT is less likely to contribute to cervical intraepithelial neoplasia or squamous cell carcinoma. Previous reports suggested that coinfection with *CT*and HPV is common in ASCUS and could contribute to the development of intraepithelial lesions \[[@B18]-[@B24]\]. It is possible that the modulation of cervical immune responses in response to *CT*may influence the clearance of HPV lesions \[[@B18],[@B19]\], and suggesting that *CT*infection with HPV persistence is not a coincidence \[[@B20]\]. Likewise, we are the first to document the prevalence of coinfection of *GBS*and HR-HPV in negative cytology (including RCC and ASCUS). However, it remains uncertain that GBS may be an independent factor or cofactor for HPV in the development of cervical intraepithelial neoplasm. For identification of its cofactor, novel immune evasion strategies and the analysis of their functions in the context of viral and bacterial infections should be required in further studies.

We compared high-throughput HPV detection methods in the present study, and found that discrepancies with direct sequencing were observed only in 10.6%. The microarray (DNA chip) method also resulted in a significant number of false negative results. Analysis of 25discordant samples showed that multiplex PCR-HPV method exhibited the highest sensitivity, positive predictive value, and accuracy. However, each HPV detection method covered different genotypes, and different typing or grouping methods were used to present the data. For example, the relatively low sensitivity of HC2 may be due to its inability to detect LR genotypes, and its lower positive predictive values and accuracy may be due to limitations in detecting individual genotypes, and thus, multiple infections.

Conclusions
===========

In conclusion, asymptomatic women of reproductive age with negative cytologic findings had a high frequency of infection with *GV, UU, GBS*, and *MH*. Most HPV infections were not associated with any specific STI pathogen; however, LR-HPV infection correlated with *CT*infection, and HR-HPV with *GBS*infection. In terms of sensitivity and prediction value, multiplex PCR yielded data most similar to that of DNA microarray.
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Short Summary
=============

Two hundred thirty-eight asymptomatic women of reproductive age with negative cytology had high frequency of sexually-transmitted infection (96.6%), and 24.4% had HPV.
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